Condition
Non-24 Hour Sleep-Wake Disorder
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Terminated2
Completed2
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03980340Terminated
Breath Biomarkers for Sleep Loss and Circadian Timing
NCT03956745Terminated
Biomarkers for Circadian Timing in Healthy Adults
NCT02776215Phase 1Completed
Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
NCT00972075Phase 2CompletedPrimary
Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects
Showing all 4 trials